Exhibit 99.1

                                                           Investor Inquiries:
                                                           Robert K. Gudbranson
                                                           (440) 329-6001

NEWS RELEASE


INVACARE CORPORATION ANNOUNCES NEW REVOLVING CREDIT FACILITY

ELYRIA,  Ohio - (January  19,  2004) - Invacare  Corporation  (NYSE:  IVC) today
announced  that  it has  entered  into a new  revolving  credit  facility  for a
five-year  term.  The $450 million  credit  facility  replaces the previous $325
million facility and refinances the bridge loan in place to fund the purchase of
WP Domus GmbH in September  2004. The new facility also has a provision to allow
Invacare and its banks to increase the facility by an additional $100 million to
$550  million.  The  Company's  spread at which it borrows  above LIBOR has been
reduced from a range of 0.675% to 1.4% under the previous facility to a range of
0.35% to 0.675% under the new facility.

Gregory C. Thompson,  senior vice president and chief financial officer,  stated
"Invacare is pleased to complete  the  renegotiation  of its credit  facility on
favorable  terms.  The strong interest from the bank group in entering into this
new facility reflects Invacare's sound financial condition and market leadership
in its industry."

Invacare  Corporation  (NYSE:IVC),  headquartered in Elyria, Ohio, is the global
leader in the manufacture and distribution of innovative home and long-term care
medical  products that promote recovery and active  lifestyles.  The Company has
5,700  associates and markets its products in 80 countries around the world. For
more information about the Company and our products, visit Invacare's website at
www.invacare.com.

This press release contains forward-looking statements within the meaning of the
"Safe Harbor"  provisions  of the Private  Securities  Litigation  Reform Act of
1995. Terms such as "will," "should," "plan,"  "intend,"  "expect,"  "continue,"
"forecast", "believe," "anticipate" and "seek," as well as similar comments, are
forward-looking  in nature.  Actual results and events may differ  significantly
from those expressed or anticipated as a result of risks and uncertainties which
include, but are not limited to, the following:  pricing pressures,  the success
of the Company's ongoing efforts to reduce costs, increasing raw material costs,
the  consolidations  of  health  care  customers  and  competitors,   government
reimbursement  issues  (including  those that affect the sales of and margins on
product,  along with the  viability of  customers)both  at the federal and state
level,  the  ability to  design,  manufacture,  distribute  and  achieve  market
acceptance of new products with higher functionality and lower costs, the effect
of  offering  customers  competitive  financing  terms,  Invacare's  ability  to
successfully identify,  acquire and integrate strategic acquisition  candidates,
the difficulties in managing and operating  businesses in many different foreign
jurisdictions (including the recent Domus acquisition), the timely completion of
facility   consolidations,   the  vagaries  of  any   litigation  or  regulatory
investigations  that  the  Company  may be or  become  involved  in at any  time
(including  the   previously-disclosed   litigation   with   Respironics),   the
difficulties  in acquiring and maintaining a proprietary  intellectual  property
ownership position, the overall economic,  market and industry growth conditions
(including   the  impact  that  acts  of  terrorism  may  have  on  such  growth
conditions),  foreign  currency and interest rate risks,  Invacare's  ability to
improve  financing  terms  and  reduce  working  capital,  as well as the  risks
described  from time to time in Invacare's  reports as filed with the Securities
and Exchange  Commission.  We undertake no  obligation to review or update these
forward-looking statements or other information contained herein.

                                       ###